Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma.
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Hereditary paraganglioma syndrome has recently been shown to be caused by germline heterozygous mutations in three (SDHB, SDHC, and SDHD) of the four genes that encode mitochondrial succinate dehydrogenase. Extraparaganglial component neoplasias have never been previously documented. In a population-based registry of symptomatic presentations of phaeochromocytoma/paraganglioma comprising 352 registrants, among whom 16 unrelated registrants were SDHB mutation positive, one family with germline SDHB mutation c.847-50delTCTC had two members with renal cell carcinoma (RCC), of solid histology, at ages 24 and 26 years. Both also had paraganglioma. A registry of early-onset RCCs revealed a family comprising a son with clear-cell RCC and his mother with a cardiac tumor, both with the germline SDHB R27X mutation. The cardiac tumor proved to be a paraganglioma. All RCCs showed loss of the remaining wild-type allele. Our observations suggest that germline SDHB mutations can predispose to early-onset kidney cancers in addition to paragangliomas and carry implications for medical surveillance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Also, clinical similarities besides pheochromocytoma have been noted in families with germline mutations of VHL and SDHB [26].”
From A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas (2005) · cites this paper as [26]
Citations
Cites
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.-M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,973
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638 · cited 3×
“00 cinate dehydrogenase (SDH), were described in families with head and neck PGLs (Baysal et al. 2000).”
BackgroundInfluentialThe Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635 · cited 6×
“It is interesting that germline FH mutations are associated with HLRCC (Tomlinson et al. 2002).”
BackgroundInfluentialOhh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Schmidt, L., Duh, F.-M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,524
Germ-Line Mutations in Nonsyndromic Pheochromocytoma
Neumann, H. P. H., Bausch, B., McWhinney, S. R., Bender, B. U., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020152 · Cited by 1,367
Self-citationNickerson, M. L., Warren, M. B., Toro, J. R., Matrosova, V., Glenn, G., Turner, M. L., Duray, P., Merino, M., Choyke, P., Pavlovich, C. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00104-6 · Cited by 940 · cited 2×
“Germline mutations in HRPT2 have been recently associated with hyperparathyroidism jaw tumor syndrome (MIM 145001), and germline mutations in BHD, encoding folliculin, have been associated with Birt-Hogg-Dubé syndrome (MIM 135150); both of these diseases have RCC as component tumors (Khoo et al. 2002; Nickerson et al.…”
BackgroundChen, F., Kishida, T., Yao, M., Hustad, T., Glavac, D., Dean, M., Gnarra, J. R., Orcutt, M. L., Duh, F. M., Glenn, G., et al. (1995) · Human Mutation · doi:10.1002/humu.1380050109 · Cited by 556
Activating mutations for the Met tyrosine kinase receptor in human cancer
Jeffers, M., Schmidt, L., Nakaigawa, N., Webb, C. P., Weirich, G., Kishida, T., Zbar, B., & Vande Woude, G. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.21.11445 · Cited by 442 · cited 4×
“Accumulation of reactive oxygen species could result from dysfunction in mitochondrial energy metabolism; results supporting this theory have been reported (Jeffers et al. 1997; Eng et al. 2003).”
BackgroundResultInfluentialA role for mitochondrial enzymes in inherited neoplasia and beyond
Eng, C., Kiuru, M., Fernandez, M. J., & Aaltonen, L. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1013 · Cited by 392 · cited 10×
“It is interesting that germline mutations in genes encoding two other subunits of SDH (mitochondrial complex II), SDHB (MIM 185470 and MIM 605373) and SDHC (MIM 602413), were found to be associated with heritable pheochromocytoma and/or PGL (Maher and Eng 2002; Eng et al. 2003).”
BackgroundResultInfluentialSelf-citation
Cited by
Wallace, D. C. (2005) · Annual Review of Genetics · doi:10.1146/annurev.genet.39.110304.095751 · Cited by 3,185
“(162), and SDHB (iron-sulfur) subunit (11, 227).”
Cohen, H. T., & McGovern, F. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043172 · Cited by 1,554
Isaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.017 · Cited by 958
“, 2001), and individuals may be predisposed to early onset renal cancer (Vanharanta et al., 2004).”
BackgroundNeumann, H. P. H. (2004) · JAMA · doi:10.1001/jama.292.8.943 · Cited by 893
Self-citationPollard, P. J., Brière, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi227 · Cited by 865
“Clear cell renal carcinomas are a feature of VHL disease (22) and recently have been reported in a HPGL family (23).”
BackgroundmtDNA mutations increase tumorigenicity in prostate cancer
Petros, J. A., Baumann, A. K., Ruiz-Pesini, E., Amin, M. B., Sun, C. Q., Hall, J., Lim, S., Issa, M. M., Flanders, W. D., Hosseini, S. H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408894102 · Cited by 836
Mitochondrial mutations in cancer
Brandon, M., Baldi, P., & Wallace, D. C. (2006) · Oncogene · doi:10.1038/sj.onc.1209607 · Cited by 818
“The linkage of mutations in nDNA-encoded mitochondrial gene mutations to cancer (Baysal et al., 2000; Niemann and Muller, 2000; Astuti et al., 2001; Lehtonen et al., 2004; Vanharanta et al., 2004) raises the possibility that mtDNA mutations might also contribute to cancer etiology.”
BackgroundThe genetic basis of kidney cancer: a metabolic disease
Linehan, W. M., Srinivasan, R., & Schmidt, L. S. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.47 · Cited by 744
“(76;77) Individuals with these hereditary conditions are at risk for the development of extraadrenal paraganglioma or pheochromocytoma and carotid body tumors.”
BackgroundPheochromocytoma and Paraganglioma
Neumann, H. P. H., Young, W. F., & Eng, C. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1806651 · Cited by 736
Self-citationSuccinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer
King, A., Selak, M. A., & Gottlieb, E. (2006) · Oncogene · doi:10.1038/sj.onc.1209594 · Cited by 672
“SDHB mutations are also associated with higher incidences of malignant and metastatic tumours such as malignant phaeochromocytoma and, in some cases, renal cell carcinoma (Vanharanta et al., 2004).”
BackgroundMitochondrial tumour suppressors: a genetic and biochemical update
Gottlieb, E., & Tomlinson, I. P. M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1737 · Cited by 621
“All of the tumours studied showed loss of the germline wild-type allel”
BackgroundThe emerging role and targetability of the TCA cycle in cancer metabolism
Anderson, N. M., Mucka, P., Kern, J. G., & Feng, H. (2018) · Protein & Cell · doi:10.1007/s13238-017-0451-1 · Cited by 556
Succinate, an intermediate in metabolism, signal transduction, ROS, hypoxia, and tumorigenesis
Tretter, L., Patocs, A., & Chinopoulos, C. (2016) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2016.03.012 · Cited by 539
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
“Loss of SDH function leads to succinate accumulation, which inhibits alpha-ketoglutarate-dependent dioxygenases and stabilizes HIFs, promoting tumorigenesis [228, 229].”
BackgroundPheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity
Dahia, P. L. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3648 · Cited by 545
Succinate dehydrogenase – Assembly, regulation and role in human disease
Rutter, J., Winge, D. R., & Schiffman, J. D. (2010) · Mitochondrion · doi:10.1016/j.mito.2010.03.001 · Cited by 462
“Renal tumors have been described in patients with underlying SDHB mutations, including renal cell carcinoma (Neumann et al., 2004; Vanharanta et al., 2004; Ricketts et al., 2008) and oncocytoma (benign renal tumor) (Henderson et al., 2009).”
BackgroundA HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas
Dahia, P. L. M., Ross, K. N., Wright, M. E., Hayashida, C. Y., Santagata, S., Barontini, M., Kung, A. L., Sanso, G., Powers, J. F., Tischler, A. S., et al. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010008 · Cited by 443
“Also, clinical similarities besides pheochromocytoma have been noted in families with germline mutations of VHL and SDHB [26].”
InfluentialOoi, A., Wong, J.-C., Petillo, D., Roossien, D., Perrier-Trudova, V., Whitten, D., Min, B. W. H., Tan, M.-H., Zhang, Z., Yang, X. J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.024 · Cited by 401
“Both VHL and SDH mutations are associated with clearcell renal cell carcinoma (CCRCC), pheochromocytoma, and paraganglioma (Vanharanta et al., 2004).”
BackgroundBardella, C., Pollard, P. J., & Tomlinson, I. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2011.07.003 · Cited by 395
Miettinen, M., Wang, Z.-F., Sarlomo-Rikala, M., Osuch, C., Rutkowski, P., & Lasota, J. (2011) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3182260752 · Cited by 363
“Renal cell carcinoma has been reported to be associated with SDHB paraganglioma syndrome, and this tumor is also otherwise known to be associated with the pseudohypoxia pathway.(36) Esophageal leiomyoma or adrenal adenoma, other tumors seen in Carney Triad,(5) were not seen in our patients.”
BackgroundGenetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas
Welander, J., Söderkvist, P., & Gimm, O. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0170 · Cited by 355
“Apart from PCCs and PGLs, SDHB mutations have been associated with renal cell carcinoma (Neumann et al. 2004, Vanharanta et al. 2004, Ricketts et al. 2008, 2010).”
BackgroundGill, A. J., Hes, O., Papathomas, T., Šedivcová, M., Tan, P. H., Agaimy, A., Andresen, P. A., Kedziora, A., Clarkson, A., Toon, C. W., et al. (2014) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000292 · Cited by 347
Germline SDHB Mutations and Familial Renal Cell Carcinoma
Ricketts, C., Woodward, E. R., Killick, P., Morris, M. R., Astuti, D., Latif, F., & Maher, E. R. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn254 · Cited by 342
Ricketts, C. J., Forman, J. R., Rattenberry, E., Bradshaw, N., Lalloo, F., Izatt, L., Cole, T. R., Armstrong, R., Kumar, V. K. A., Morrison, P. J., et al. (2010) · Human Mutation · doi:10.1002/humu.21136 · Cited by 337
“Previously, an apparent overrepresentation of 50 mutations in SDHB patients with renal cancer has been noted [Vanharanta et al., 2004; Ricketts et al., 2008], but there was no statistically significant association between 50 mutations (in the first 300 nucleotides) and RCC risk or risk of malignant PCC.”
BackgroundInfluentialTargeting mitochondrial metabolism for precision medicine in cancer
Sainero-Alcolado, L., Liaño-Pons, J., Ruiz-Pérez, M. V., & Arsenian-Henriksson, M. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-01022-y · Cited by 322
Metabolic reprogramming and epithelial‐to‐mesenchymal transition in cancer
Sciacovelli, M., & Frezza, C. (2017) · The FEBS Journal · doi:10.1111/febs.14090 · Cited by 329
The Metabolic Basis of Kidney Cancer
Linehan, W. M., Schmidt, L. S., Crooks, D. R., Wei, D., Srinivasan, R., Lang, M., & Ricketts, C. J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1354 · Cited by 306
VHL and HIF signalling in renal cell carcinogenesis
Baldewijns, M. M., van Vlodrop, I. J., Vermeulen, P. B., Soetekouw, P. M., van Engeland, M., & de Bruïne, A. P. (2010) · The Journal of Pathology · doi:10.1002/path.2689 · Cited by 316
“An association between early-onset RCC and mutations in SDHB has been reported [24].”
BackgroundWei, M.-H., Toure, O., Glenn, G. M., Pithukpakorn, M., Neckers, L., Stolle, C., Choyke, P., Grubb, R., Middelton, L., Turner, M. L., et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.033506 · Cited by 313
“Furthermore, three cases with kidney cancer and germline mutations in SHD-B have been reported [19].”
BackgroundMitochondria and Cancer: Warburg Addressed
WALLACE, D. C. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.035 · Cited by 285
Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis
Cardaci, S., Zheng, L., MacKay, G., van den Broek, N. J. F., MacKenzie, E. D., Nixon, C., Stevenson, D., Tumanov, S., Bulusu, V., Kamphorst, J. J., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3233 · Cited by 286
“…mutations in the human genes for any of the SDH subunits, or the SDH complex assembly factor (SDHAF2), are associated with susceptibility to develop neuroendrocrine neoplasms, gastrointestinal stromal tumours as well as renal cell carcinoma (RCC) 2 , 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 .”
Ripperger, T., Bielack, S. S., Borkhardt, A., Brecht, I. B., Burkhardt, B., Calaminus, G., Debatin, K., Deubzer, H., Dirksen, U., Eckert, C., et al. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38142 · Cited by 283
Gill, A. J., Benn, D. E., Chou, A., Clarkson, A., Muljono, A., Meyer-Rochow, G. Y., Richardson, A. L., Sidhu, S. B., Robinson, B. G., & Clifton-Bligh, R. J. (2010) · Human Pathology · doi:10.1016/j.humpath.2009.12.005 · Cited by 277
Timmers, H. J. L. M., Kozupa, A., Eisenhofer, G., Raygada, M., Adams, K. T., Solis, D., Lenders, J. W. M., & Pacak, K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2315 · Cited by 276
“Among 53 SDHB mutation carriers, two patients from the same family had renal clear cell carcinoma at young age and one patient with a different mutation had a papillary thyroid carcinoma at age 14 yr (9, 37).”
BackgroundThe NGS in PPGL (NGSnPPGL) Study Group, Toledo, R. A., Burnichon, N., Cascon, A., Benn, D. E., Bayley, J.-P., Welander, J., Tops, C. M., Firth, H., Dwight, T., et al. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.185 · Cited by 275
Revisiting the TCA cycle: signaling to tumor formation
Raimundo, N., Baysal, B. E., & Shadel, G. S. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.06.001 · Cited by 271
“Finally, mutations in SDHB are associated with renal cell carcinoma and T-cell acute leukemia [18, 19], and mutations in SDHB, SDHC and SDHD are associated with gastrointestinal stromal tumors [20].”
BackgroundPasini, B., & Stratakis, C. A. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02111.x · Cited by 273
“…by LOH at 11q23 (table 10) (group 2B neuroblastomas, midgut carcinoids, neuroendocrine tumours, PHEOs from carriers of VHL missense mutations) [32, 129, 149, 150, 153–157] could suggest a role in tumourigenesis through a mechanism of haploinsufficiency, supported by the consistent reduction of…”
Renal Cell Carcinoma in Tuberous Sclerosis Complex
Yang, P., Cornejo, K. M., Sadow, P. M., Cheng, L., Wang, M., Xiao, Y., Jiang, Z., Oliva, E., Jozwiak, S., Nussbaum, R. L., et al. (2014) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000237 · Cited by 265
“Antigen retrieval was achieved by heating sections in citrate-based solution (pH 6.0, Leica) for CK7, CA-IX, and HMB45, or EDTAbased solution (pH 9.0, Leica) for TFE3, AMACR, CD10, vimentin, CD117, PAX8, and SDHB. Bound antibodies were localized using Polymer Refine Kit (Leica) or Ultra Vision LP Detection System HRP…”
BackgroundInfluentialShroff, E. H., Eberlin, L. S., Dang, V. M., Gouw, A. M., Gabay, M., Adam, S. J., Bellovin, D. I., Tran, P. T., Philbrick, W. M., Garcia-Ocana, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507228112 · Cited by 255
Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics
Linehan, W. M. (2012) · Genome Research · doi:10.1101/gr.131110.111 · Cited by 243
“velopment of pheochromocytomas and paragangliomas and kidney cancer (Vanharanta et al. 2004).”
BackgroundSuccinate Dehydrogenase Kidney Cancer: An Aggressive Example of the Warburg Effect in Cancer
Ricketts, C. J., Shuch, B., Vocke, C. D., Metwalli, A. R., Bratslavsky, G., Middelton, L., Yang, Y., Wei, M.-H., Pautler, S. E., Peterson, J., et al. (2012) · Journal of Urology · doi:10.1016/j.juro.2012.08.030 · Cited by 240
“Germline mutation of the Krebs cycle (tricarboxylic acid cycle) enzyme fumarate hydratase is associated with an aggressive form of type II papillary kidney cancer in patients with HLRCC.2–4 In fumarate hydratase deficient kidney cancer, a prototypic example of the Warburg effect in cancer, oxidative phosphorylation is…”
BackgroundWilliamson, S. R., Eble, J. N., Amin, M. B., Gupta, N. S., Smith, S. C., Sholl, L. M., Montironi, R., Hirsch, M. S., & Hornick, J. L. (2015) · Modern Pathology · doi:10.1038/modpathol.2014.86 · Cited by 225
Zdzisińska, B., Żurek, A., & Kandefer-Szerszeń, M. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0406-x · Cited by 221
“…al. 2000, 2002; Burnichon et al. 2010; Niemann and Muller 2000), pheochromocytomas (Astuti et al. 2001), renal cell carcinoma (Ricketts et al. 2008; Vanharanta et al. 2004), T cell acute leukaemia (Baysal 2007), and gastrointestinal stromal tumours (Italiano et al. 2012; Janeway et al. 2011;…”
BackgroundNi, Y., Zbuk, K. M., Sadler, T., Patocs, A., Lobo, G., Edelman, E., Platzer, P., Orloff, M. S., Waite, K. A., & Eng, C. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.07.011 · Cited by 222
Self-citationOncometabolites in renal cancer
Yong, C., Stewart, G. D., & Frezza, C. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0210-z · Cited by 217
Searching for the hereditary causes of renal-cell carcinoma
Pavlovich, C. P., & Schmidt, L. S. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1364 · Cited by 209
“Recently, germline mutations in succinate dehydrogenase B, another enzyme in the Krebs cycle, were found in patients with hereditary paraganglioma syndrome who developed early onset renal cance”
BackgroundHereditary Kidney Cancer Syndromes
Haas, N. B., & Nathanson, K. L. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2013.10.001 · Cited by 208
Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background
Fishbein, L., & Nathanson, K. L. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.01.009 · Cited by 208
15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1–5
Benn, D. E., Robinson, B. G., & Clifton-Bligh, R. J. (2015) · Endocrine-Related Cancer · doi:10.1530/erc-15-0268 · Cited by 197
“This is particularly true for SDHA (PGL5) and SDHC (PGL3), for which penetrance appears to be much lower than for SDHB (PGL4) and SDHD (PGL1).”
BackgroundInfluentialNeumann, H. P. H., Erlic, Z., Boedeker, C. C., Rybicki, L. A., Robledo, M., Hermsen, M., Schiavi, F., Falcioni, M., Kwok, P., Bauters, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4057 · Cited by 194
“This type of surveillance will detect incidental ‘‘other’’ tumors including those of the kidneys, thyroid, and gastrointestinal stromal tumors (19, 22).”
BackgroundSelf-citationRenal Tumors Associated With Germline SDHB Mutation Show Distinctive Morphology
Gill, A. J., Pachter, N. S., Chou, A., Young, B., Clarkson, A., Tucker, K. M., Winship, I. M., Earls, P., Benn, D. E., Robinson, B. G., et al. (2011) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318227e7f4 · Cited by 191
“Historically, the renal tumors associated with PGL4 have usually been classified as carcinoma but have sometimes been classified as oncocytoma.(4,10,15,21,22,24) We recently demonstrated negative immunohistochemical labeling for SDHB in 3 SDHB mutation-related renal tumors but in none of 70 unselected renal tumors.”
BackgroundCarlo, M. I., Mukherjee, S., Mandelker, D., Vijai, J., Kemel, Y., Zhang, L., Knezevic, A., Patil, S., Ceyhan-Birsoy, O., Huang, K.-C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1986 · Cited by 187
Oncometabolites: Unconventional triggers of oncogenic signalling cascades
Sciacovelli, M., & Frezza, C. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.025 · Cited by 178
International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers
Amar, L., Pacak, K., Steichen, O., Akker, S. A., Aylwin, S. J. B., Baudin, E., Buffet, A., Burnichon, N., Clifton-Bligh, R. J., Dahia, P. L. M., et al. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00492-3 · Cited by 170
Self-citationMolecular Diagnosis and Therapy of Kidney Cancer
Linehan, W. M., Bratslavsky, G., Pinto, P. A., Schmidt, L. S., Neckers, L., Bottaro, D. P., & Srinivasan, R. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.042808.171650 · Cited by 167
“Renal carcinoma, along with pheochromocytoma/paraganglioma, has been found to be a component of the familial pheochromocytoma/paraganglioma complex(24,51,72,83) and a recent report described germline SDHB mutations in a family with renal cancer with no history of pheochromocytoma.”
BackgroundMaxwell, P. H. (2005) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2005.03.001 · Cited by 167
Xekouki, P., Pacak, K., Almeida, M., Wassif, C. A., Rustin, P., Nesterova, M., de la Luz Sierra, M., Matro, J., Ball, E., Azevedo, M., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1179 · Cited by 164
Bayley, J.-P., Launonen, V., & Tomlinson, I. P. (2008) · BMC Medical Genetics · doi:10.1186/1471-2350-9-20 · Cited by 162
“Phenotypically, both HPGL and VHL patients may develop pheochromocytomas, and the clear cell renal carcinomas that are a major feature of VHL disease [28] have recently been reported in a HPGL family [29].”
BackgroundState of the Science: An Update on Renal Cell Carcinoma
Jonasch, E., Futreal, P. A., Davis, I. J., Bailey, S. T., Kim, W. Y., Brugarolas, J., Giaccia, A. J., Kurban, G., Pause, A., Frydman, J., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0117 · Cited by 162
“Heterozygous germline mutations in SDH subunits predispose to pheochromocytoma/paraganglioma, and mutations in SDHB and SDHD have also been associated with RCC (6, 126).”
BackgroundTargeting MTHFD2 in acute myeloid leukemia
Pikman, Y., Puissant, A., Alexe, G., Furman, A., Chen, L. M., Frumm, S. M., Ross, L., Fenouille, N., Bassil, C. F., Lewis, C. A., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151574 · Cited by 159
“, 2001), renal cell cancer (Vanharanta et al., 2004), and gastrointestinal stromal tumors (Janeway et al.”
BackgroundGenetic predisposition to kidney cancer
Schmidt, L. S., & Linehan, W. M. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.09.001 · Cited by 160
“Vanharanta et al reported PGL/PCC and RCC in two families with early age of renal tumor onset (<30 years) and variable histologies who harbored germline mutations in the SDHB gene encoding subunit B of the Krebs cycle enzyme succinate dehydrogenase [77].”
BackgroundXekouki, P., Szarek, E., Bullova, P., Giubellino, A., Quezado, M., Mastroyannis, S. A., Mastorakos, P., Wassif, C. A., Raygada, M., Rentia, N., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4297 · Cited by 159
Self-citationHereditary leiomyomatosis and renal cell carcinoma
Schmidt, L. S., & Linehan, W. M. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s42097 · Cited by 168
“…germline mutations in genes that encode components of the tricarboxylic acid (TCA) cycle, including the subunits B, C and D of succinate dehydrogenase (SDH) 17–19 and the FH gene, 20 predispose individuals to unique inherited renal cancer syndromes and drive metabolic reprogramming of renal tumors.”
Papathomas, T. G., Gaal, J., Corssmit, E. P. M., Oudijk, L., Korpershoek, E., Heimdal, K., Bayley, J., Morreau, H., van Dooren, M., Papaspyrou, K., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0623 · Cited by 147
The metabolic basis of kidney cancer
Linehan, W. M., & Ricketts, C. J. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.06.002 · Cited by 144
Clinical Review on the Management of Metastatic Renal Cell Carcinoma
Tran, J., & Ornstein, M. C. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00419 · Cited by 150
Malignant Head and Neck Paragangliomas in SDHB Mutation Carriers
Boedeker, C. C., Neumann, H. P. H., Maier, W., Bausch, B., Schipper, J. H., & Ridder, G. J. (2007) · Otolaryngology · doi:10.1016/j.otohns.2007.01.015 · Cited by 159
“On the other hand, malignant paraganglial tumors frequently occur in patients with mutations of the SDHB gene.(1,5,14,15,18) In the present study, none of the 5 SDHC and none of the 45 SDHD mutation carriers presented with a malignant HNP.”
BackgroundSelf-citationJiménez, C., Cote, G., Arnold, A., & Gagel, R. F. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2178 · Cited by 137
The role of complex II in disease
Hoekstra, A. S., & Bayley, J. (2012) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.11.005 · Cited by 154
“A variety of other types of renal tumors have been described in patients with SDHB mutations, including chromophobic RCC, type II papillary RCC, and oncocytoma [65–68].”
BackgroundClinical aspects of SDHx-related pheochromocytoma and paraganglioma
Timmers, H. J. L. M., Gimenez-Roqueplo, A.-P., Mannelli, M., & Pacak, K. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-08-0284 · Cited by 131
“2004, Vanharanta et al .”
The epigenetic landscape of renal cancer
Morris, M. R., & Latif, F. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.168 · Cited by 147
Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies
Costa, L. J., & Drabkin, H. A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1404 · Cited by 142
“Another pathway of HIF accumulation and RCC developmentinvolvesKrebscycleenzymemutations:succinatedehydrogenase (SDH)-B mutations [ 16 ] cause clear-cell RCC, while mutations of fumarate hydratase [17] cause typeIIpapillarycancer.InSDHmutations,accumulationof succinate directly inhibits proline hydroxylase and HIFleve…”
BackgroundProtein-mediated assembly of succinate dehydrogenase and its cofactors
Van Vranken, J. G., Na, U., Winge, D. R., & Rutter, J. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2014.990556 · Cited by 122
“Finally, the link between RCC and SDH dysfunction is supported by the discovery of two families with inherited renal cell tumor syndromes resulting from germline mutations in SDHB (Vanharanta et al., 2004).”
BackgroundSDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery
Saxena, N., Maio, N., Crooks, D. R., Ricketts, C. J., Yang, Y., Wei, M.-H., Fan, T. W. ‐., Lane, A. N., Sourbier, C., Singh, A., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv287 · Cited by 133
“An understanding of SDHrelated tumorigenesis is crucial because mutations in succinate dehydrogenase genes, including SDHB, increase susceptibility to development of paragangliomas and pheochromocytomas (17,18), renal cell carcinoma (6,8), and gastrointestinal stromal tumors (19).”
BackgroundMetabolic reprogramming and the role of mitochondria in polycystic kidney disease
Podrini, C., Cassina, L., & Boletta, A. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109495 · Cited by 129
Succinate: An initiator in tumorigenesis and progression
Zhao, T., Mu, X., & You, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.17734 · Cited by 126
“In the case of renal cell carcinoma and papillary thyroid cancer, dysfunction of the SDHB domain is the greatest risk factor [36, 37].”
BackgroundTHERAPY OF ENDOCRINE DISEASE: Treatment of malignant pheochromocytoma and paraganglioma
Baudin, É., Habra, M. A., Deschamps, F., Cote, G. J., Dumont, F., Cabanillas, M. E., Arfi, J., Berdelou, A., Moon, B., Ghuzlan, A. A., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0113 · Cited by 133
Smith, S. C., Sirohi, D., Ohe, C., McHugh, J. B., Hornick, J. L., Kalariya, J. J., Karia, S., Snape, K. M. G., Hodgson, S. V., Cani, A. K., et al. (2017) · Histopathology · doi:10.1111/his.13183 · Cited by 114
Ni, Y., He, X., Chen, J., Moline, J., Mester, J. L., Orloff, M. S., Ringel, M. D., & Eng, C. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr459 · Cited by 126
“We subsequently noticed a small subset of individuals with germline SDHB mutations in our population-based PCC registry also developed early onset renal cell carcinoma (RCC) and papillary thyroid carcinoma, reminiscent of two CS component tumors (12,13).”
BackgroundSelf-citationFamilial SDHA Mutation Associated With Pituitary Adenoma and Pheochromocytoma/Paraganglioma
Dwight, T., Mann, K., Benn, D. E., Robinson, B. G., McKelvie, P. A., Gill, A. J., Winship, I., & Clifton-Bligh, R. J. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1400 · Cited by 118
Tumor metabolism as modulator of immune response and tumor progression
Gottfried, E., Kreutz, M. P., & Mackensen, A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.009 · Cited by 125
Desideri, E., Vegliante, R., & Ciriolo, M. R. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.023 · Cited by 124
“renal cell carcinoma or T cell acute leukemia also exists [28,33,34].”
BackgroundHereditary kidney cancer: Unique Opportunity for Disease‐based Therapy
Linehan, W. M., Pinto, P. A., Bratslavsky, G., Pfaffenroth, E. C., Merino, M. J., Vocke, C. D., Toro, J. R., Bottaro, D. P., Neckers, L., Schmidt, L. S., et al. (2009) · Cancer · doi:10.1002/cncr.24230 · Cited by 112
“Hereditary paraganglioma/pheochromocytoma, an autosomal-dominant hereditary condition in which affected individuals are at risk for the development of pheochromocytoma and extra-adrenal pheochromocytomas (paragangliomas) (PGL), is characterized by germline mutation of 3 of the 4 genes that encode the Krebs cycle gene,…”
BackgroundHigh-throughput sequencing in mitochondrial DNA research
Ye, F., Samuels, D. C., Clark, T. A., & Guo, Y. P. (2014) · Mitochondrion · doi:10.1016/j.mito.2014.05.004 · Cited by 115
“Since then, various studies have shown that mutations in mtDNA can contribute to cancer etiology (Baysal et al., 2000; Vanharanta et al., 2004), and mtDNAmutations are associatedwith various types of cancer, including breast cancer (Bai et al., 2007; Canter et al., 2005), prostate cancer (Herrmann…”
Evenepoel, L., Papathomas, T. G., Krol, N. M. G., Korpershoek, E., de Krijger, R. R., Persu, A., & Dinjens, W. N. M. (2014) · Genetics in Medicine · doi:10.1038/gim.2014.162 · Cited by 115
Tseng, P., Wu, W.-H., Hu, T., Chen, C., Cheng, H.-C., Li, C., Tsai, W., Tsai, H.-J., Hsieh, M.-C., Chuang, J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21361-6 · Cited by 129
Hereditary Renal Cancer Syndromes: An Update of a Systematic Review
Verine, J., Pluvinage, A., Bousquet, G., Lehmann‐Che, J., de BAZELAIRE, C., Soufir, N., & Mongiat-Artus, P. (2010) · European Urology · doi:10.1016/j.eururo.2010.08.031 · Cited by 119
Germline PTEN Mutation Cowden Syndrome: An Underappreciated Form of Hereditary Kidney Cancer
Shuch, B. M., Ricketts, C. J., Vocke, C. D., Komiya, T., Middelton, L. A., KAUFFMAN, E. C., Merino, M. J., Metwalli, A. R., Dennis, P. A., & Linehan, W. M. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.06.012 · Cited by 104
Emerging Role of TCA Cycle-Related Enzymes in Human Diseases
Kang, W., SUZUKI, M. T., Saitô, T., & Miyado, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313057 · Cited by 120
“related to renal cell carcinoma and T-cell acute leukemia [27,28], and SDHB, SDHC, and SDHD mutations result in gastrointestinal stromal tumors [29].”
BackgroundRadiogenomics in Renal Cancer Management—Current Evidence and Future Prospects
Ferro, M., Musi, G., Marchioni, M., Maggi, M., Veccia, A., Giudice, F. D., Barone, B., Crocetto, F., Lasorsa, F. M., Antonelli, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054615 · Cited by 109
SDHB-related pheochromocytoma and paraganglioma penetrance and genotype–phenotype correlations
Jochmanová, I., Wolf, K. I., King, K. S., Nambuba, J., WESLEY, R. A., Martucci, V. L., Raygada, M. J., Adams, K. T., Prodanov, T., Fojo, A. T., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2397-3 · Cited by 104
“Previous studies reported SDHB mutations in patients with gastrointestinal stromal tumors, clear cell renal carcinoma, or papillary thyroid cancer (Neumann et al. 2004; Ni et al. 2008; Ricketts et al. 2008; Vanharanta et al. 2004).”
Aerobic glycolysis: a novel target in kidney cancer
Shuch, B. M., Linehan, W. M., & Srinivasan, R. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.57 · Cited by 99
Recent developments in the treatment of renal cell carcinoma
Dutcher, J. P. (2013) · Therapeutic Advances in Urology · doi:10.1177/1756287213505672 · Cited by 96
“This mutation and syndrome has now been reported to include subjects with renal cell cancers [Vanharanta et al. 2004].”
BackgroundXekouki, P., & Stratakis, C. A. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0118 · Cited by 100
McWhinney, S. R., Pilarski, R. T., Forrester, S. R., Schneider, M. C., Sarquis, M. M., Dias, E. P., & Eng, C. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0769 · Cited by 89
“SDHB intragenic mutations, however, have been associated with nontraditional histology renal cell carcinoma at very young ages ( 14 ).”
BackgroundSelf-citationGenetics of hereditary head and neck paragangliomas
Boedeker, C. C., Hensen, E. F., Neumann, H. P. H., Maier, W., van Nederveen, F. H., Suarez, C. M., Kunst, H. P. M., Rodrigo, J. P., Takes, R. P., Pellitteri, P. K., et al. (2013) · Head & Neck · doi:10.1002/hed.23436 · Cited by 97
“Although tumor penetrance in SDHB mutation carriers seems to be slightly lower, there is an increased risk for the development of malignant paraganglial tumors in these patients.(35,65,69) Additionally, as demonstrated by Ricketts et al(69) in 2012, SDHB, SDHC, and SDHD mutation carriers all have an increased risk for…”
BackgroundSelf-citationMitochondrial Dysfunction at the Center of Cancer Therapy
Chiu, H. Y., Tay, E. X. Y., Ong, D. S. T., & Taneja, R. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7898 · Cited by 95
“Succinate dehydrogenase (SDH) is made up of several subunits such as SDHA, SDHB, and SDHC, and they were found to be commonly mutated in cancers such as gastrointestinal stromal tumors, renal cell carcinoma, and neuroblastoma, which led to SDH deficiency in cancer (41, 62, 156, 183).”
Rare insights into cancer biology
Adam, J., Yang, M., Soga, T., & Pollard, P. J. (2013) · Oncogene · doi:10.1038/onc.2013.222 · Cited by 92
Yehia, L., Niazi, F., Ni, Y., Ngeow, J. Y. Y., Sankunny, M., Liu, Z., Wei, W., Mester, J. L., Keri, R. A., Zhang, B., et al. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.10.001 · Cited by 90
Self-citationPhysiological consequences of complex II inhibition for aging, disease, and the mKATP channel
Wojtovich, A. P., Smith, C. O., Haynes, C. M., Nehrke, K. W., & Brookes, P. S. (2013) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.12.007 · Cited by 83
Metadata
- Authors
- Vanharanta, S., Buchta, M., McWhinney, S. R., Virta, S. K., Peçzkowska, M., Morrison, C. D., Lehtonen, R., Januszewicz, A., Järvinen, H., Juhola, M., Mecklin, J.-P., Pukkala, E., Herva, R., Kiuru, M., Nupponen, N. N., Aaltonen, L. A., Neumann, H. P. H., & Eng, C.
- Affiliations
- University of Helsinki (FI)
- University of Freiburg (DE)
- The Ohio State University (US)
- Institute of Cardiology (PL)
- Helsinki University Hospital (FI)
- Central Finland Health Care District (FI)
- Finnish Cancer Registry (FI)
- Oulu University Hospital (FI)
- University of Cambridge (GB)
- Corresponding author
- Eng, Charis
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2004-01
- Volume
- 74
- Issue
- 1
- Pages
- 153-159
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1181902
- OpenAlex
- W1977015709
- Cited by
- 389
- References
- 24
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 14 · 2023: 11 · 2022: 14 · 2021: 20 · 2020: 12 · 2019: 22 · 2018: 16 · 2017: 20 · 2016: 20 · 2015: 21 · 2014: 32 · 2013: 26 · 2012: 29
- FWCI
- 13.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 3487 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Funders
- National Institutes of Health
- U.S. Public Health Service (NE571/4-1)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD039058, R01 HD39058, R01HD39058-02S1)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Keywords
- SDHB mutation, hereditary paraganglioma, succinate dehydrogenase, clear cell renal cell carcinoma, cardiac paraganglioma, germline mutations, loss of heterozygosity, cancer susceptibility, medical surveillance
- MeSH terms
- Adolescent, Adult, Base Sequence, Carcinoma, Renal Cell, Female, Humans, Iron-Sulfur Proteins, Kidney Neoplasms, Male, Paraganglioma, Pedigree, Succinate Dehydrogenase, Sequence Deletion, Age of Onset, Germ-Line Mutation, Genetic Predisposition to Disease, Mutation, Missense, Protein Subunits, Siblings
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.